Recombinant Human CD79b protein (His tag) is a Human Fragment protein, in the 22 to 159 aa range, expressed in Baculovirus infected insect, with >90% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE.
A D P A R S E D R Y R N P K G S A C S R I W Q S P R F I A R K R G F T V K M H C Y M N S A S G N V S W L W K Q E M D E N P Q Q L K L E K G R M E E S Q N E S L A T L T I Q G I R F E D N G I Y F C Q Q K C N N T S E V Y Q G C G T E L R V M G F S T L A Q L K Q R N T L K D H H H H H H
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes Predicted molecular weight:18-28kDa (SDS-PAGE under reducing conditions) |
Select an associated product type
Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
CD79b, B29, IGB, CD79B, B-cell antigen receptor complex-associated protein beta chain, B-cell-specific glycoprotein B29, Ig-beta, Immunoglobulin-associated B29 protein
Recombinant Human CD79b protein (His tag) is a Human Fragment protein, in the 22 to 159 aa range, expressed in Baculovirus infected insect, with >90% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE.
pH: 7.4
Constituents: 90% PBS, 10% Glycerol (glycerin, glycerine)
Affinity purified
Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
Phosphorylated on tyrosine upon B-cell activation by SRC-type Tyr-kinases such as BLK, LYN and SYK.
CD79b also known as Ig-beta is a protein that plays a mechanical role as part of the B-cell antigen receptor complex. This protein with a mass of approximately 40 kDa is mainly expressed on the surface of B lymphocytes. It is an important component of the heterodimeric complex composed of CD79a (Ig-alpha) and CD79b which associates with membrane-bound immunoglobulins to form the B-cell receptor (BCR). CD79b is essential for transducing activation signals following antigen binding to the BCR.
The primary role of CD79b within the immune system is to support signal transduction. Upon binding of an antigen to BCR on B cells CD79b as part of the BCR complex initiates signaling cascades which lead to B-cell activation proliferation and differentiation. These processes are critical for humoral immunity ensuring adequate antibody production. CD79b is often found in association with CD19 another important B-cell surface protein and together they aid in amplifying the signals required for B-cell response.
CD79b is deeply involved in the B-cell receptor signaling pathway and the broader adaptive immune response. Once the BCR is engaged by an antigen CD79b helps activate intracellular signaling pathways that involve kinases such as SYK and BLNK which help propagate and amplify the immune response. These pathways also interact with other receptor components like CD22 and CD19 creating a network of interactions ensuring effective pathogen recognition and response.
CD79b carries significant relevance in the context of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and some types of lymphoma. Dysregulation or mutations in CD79b can affect BCR signaling leading to unchecked B-cell proliferation characteristic of these diseases. Additionally CD79b's interaction with proteins such as SYK in the signaling pathways makes it a potential therapeutic target in treating B-cell related cancers. Researchers are actively investigating anti-CD79b therapies to disrupt abnormal signaling in B-cell malignancies.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
15% SDS-PAGE analysis of ab219486 (3μg) migrating at 18-28kDa under reducing conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com